On February, 15. Investors expect Kodiak Sciences Inc. (NASDAQ:KOD) to reveal its quarterly earnings, RTT reports. Wall Street now predicts -76.69 % EPS growth despite Kodiak Sciences Inc. previous quarter’s EPS of $-1.33. The stock decreased 0.88% or $0.08 during the last trading session, touching $9.Currently Kodiak Sciences Inc. is after 0.00% change in last January 12, 2018. KOD has also 28,035 shares volume. The stock the S&P500 by 0.00%.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases.The firm is worth $339.82 million. The company’s lead product candidate is KSI-301, a vascular endothelial growth factor -biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.Last it reported negative earnings. The Company’s preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.